Introduction
The mechanism by which catecholamines stimulate ventilation in animals' and man2-4 is imperfectly understood. Noradrenaline stimulates ventilation in the cat by an action that depends on the integrity of the peripheral chemoreceptors. 5 In man the potentiating effect of noradrenaline on the ventilatory response to inhaled CO2 depends on the presence of hypoxia,6 7 suggesting a similar mechanism. Such effects on ventilation and its chemical control may be important when catecholamines are used to treat asthma and chronic bronchitis, when the mechanisms controlling breathing are already disordered.8 9 The introduction of an intravenous preparation of salbutamol, a beta2-adrenergic bronchodilator, for use in severe asthma has allowed us to study the effect of an intravenous infusion of this drug on the chemical control of ventilation in normal men. We also measured the effect of the drug on heart rate, and, since we have observed an association between hypokalaemia and changes in ventilatory control,1 0 we measured the effect of salbutamol on plasma electrolytes, these results then leading us to study serum insulin and plasma glucose during infusion of salbutamol. In one fasting subject urinary potassium excretion and venous plasma potassium were also measured after a water load at 20 minute intervals before, during, and after an infusion of salbutamol 10 (table I) .
Plasma biochemistry-The control infusion produced no significant changes in the plasma sodium, potassium, or total C02 content in the five subjects in whom measurements were made. The salbutamol infusion had no effect on plasma sodium or total CO, content but did produce a highly significant fall in the plasma potassium from 3 99 to 3 10 mmol/l (3 99 to 3-10 mEq/l) (table II) . Heart rate-The drug produced definite increases in heart rate, ranging from 250o when the subjects were breathing air to 50q0 in combined hypoxia and hypercapnia (table I) . For a given inspired C02 concentration the heart rate was significantly higher (P = 0 05) in hypoxia than in hyperoxia.
Plasma potassium and glucose and serum insulin-Plasma potassium fell progressively after the start of the infusion, reaching minimum values at the end of the infusion, and began to return towards normal within 30 minutes of stopping the infusion (fig 2) . The fall in plasma potassium was associated with increases in plasma glucose and serum insulin, which also returned towards normal after the end of the infusion.
Urinary excretion of potassium-Total urinary potassium excretion fell during the salbutamol infusion (fig 3) . This fall was closely associated with the fall in plasma potassium in the one subject studied.
Discussion
The dose of salbutamol which we used was in the middle of the dose range that causes significant bronchodilation in patients with asthmal3- 5 inability to inhibit this effect by hyperoxia argues against a role for the carotid body in mediating this response.'7 Alternatively, catecholamines may stimulate ventilation by metabolic' 18 or central nervous system3 19 actions. We suggest that the stimulation may result from a shift of potassium from the extracellular to the intracellular space, since hypokalaemia has been described in association with inappropriate stimulation of ventilation.'0 20 Further studies, using glucose and insulin infusion, are needed to investigate this possibility.
The pronounced fall in plasma potassium that we observed during salbutamol infusion was associated with rises in plasma glucose and serum insulin. Although the rise in serum insulin in two of the men was small, it was consistent and similar to the rise seen with a comparable infusion dose of isoprenaline." Salbutamol, like other beta-adrenergic agents probably stimulates glycolysis22 and insulin release,2' resulting in a shift of potassium from the extracellular to the intracellular space. The fall in urinary potassium excretion observed in one man is consistent with such an action.
Beta-adrenergic agents increase the heart rate, but salbutamol is allegedly a beta2-adrenergic agent with 10 times less effect on the heart rate than isoprenaline'4 when given by intravenous infusion to asthmatic patients. Nevertheless, the moderate ---T-therapeutic dose that we used produced a striking increase in heart rate in our normal subjects that was maximal in combined hypoxia and hypercapnia. This increased heart rate was associated in all subjects with appreciable palpitations, flushing, and minimal tremor. Undoubtedly intravenous infusions of salbutamol, in the dose which we have studied, may produce bronchodilatation in patients with stable'4 and severe'5 asthma. It is unlikely that the effects on the chemical control of ventilation which we have shown will be of much benefit when salbutamol is used in asthma, for in such patients the ventilatory drive is already considerably increased. The drug may be valuable in increasing ventilatory drive in bronchitic patients with the hypercapnia of chronic ventilatory failure. 9 We are concerned at the pronounced tachycardia that occurred during salbutamol infusion for serious cardiac dysrhythmias may result23 24 Summary Factors B and D as well as the total activity of the alternative pathway of complement activation were measured using a functional assay in sera from 29 patients with sickle cell anaemia and 18 normal controls. Total alternative pathway activity was reduced in the patients compared with controls. In patients with abnormally low total alternative pathway activity factor D levels were normal, whereas factor B levels were significantly depressed-to a mean level of about half of normal. Regression analysis in patients also showed a significant relation between total alternative pathway activity and factor B levels. A deficiency of factor B is the likely cause Introduction Bacterial infection accounts for 30-40% of the mortality in patients with sickle cell anaemia,' 2the pneumococcus and Gramnegative pyogenic organisms being the commonest pathogens concerned.' 3 4 A possible mechanism for this proneness to severe infection has been suggested by the report of a deficiency in the capacity of serum from patients with sickle cell anaemia to opsonify pneumococci.5 6 Alternative pathway function appears to be more critical than classical pathway function to the bactericidal effect of normal serum,7 and the defect in sickle cell sera may result from a selective abnormality of the alternative pathway by which the third component of complement (C3), the essential opsonin, is activated; in these patients opsonification by the classical pathway is normal. 6 Although their precise interactions are not fully understood the main serum factors that interact to generate C3 convertase by the alternative pathway have been defined: they are properdin, factors B (C3 proactivator or glycine-rich p3-glycoprotein) and D (C3 proactivator convertase), and Mg++.7-11 We assessed total alternative pathway function in patients with sickle cell anaemia and attempted to define the relative contributions of factors B and D to any defects observed.
